Top

Current Hematologic Malignancy Reports

Published in:

01-04-2018 | Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors)

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

Authors: Nicholas J. Short, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi

Published in: Current Hematologic Malignancy Reports | Issue 2/2018

Abstract

Purpose of Review

Older adults with acute lymphoblastic leukemia (ALL) have worse survival compared to their younger counterparts. Here, we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic approaches to ALL in the elderly population.

Recent Findings

The poor outcomes of older adults with ALL are driven largely by lack of tolerance to standard-dose chemotherapy, which leads to unacceptably high rates of myelosuppression-related deaths. Recent studies have shown promising results with the use of low-intensity or chemotherapy-free regimens in older patients with ALL, which are able to retain efficacy without excess toxicity.

Summary

Novel antibody constructs such as inotuzumab ozogamicin and blinatumomab as well as potent later-generation tyrosine kinase inhibitors such as ponatinib hold significant promise in the management of ALL in the older adult. Innovative combination strategies may further improve the outcomes of these patients.

National Cancer Institute. Cancer stat facts: acute lymphocytic leukemia (ALL). In: Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/alyl.html. Accessed 11/21/17 2017.

Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–65. https://doi.org/10.1200/jco.2008.20.8983. CrossRefPubMed

Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52. https://doi.org/10.1056/NEJMra1400972. CrossRefPubMed

•• Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–71. https://doi.org/10.1111/j.1365-2141.2012.09095.x. Showed worse outcomes for older adults compared to their younger counterparts and evaluated predictors for survival in the older population.CrossRefPubMedPubMedCentral

Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–50. https://doi.org/10.1182/blood-2013-09-529008.CrossRefPubMedPubMedCentral

Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–7. https://doi.org/10.1182/blood-2005-04-1623.CrossRefPubMed

Gokbuget N. How I treat older patients with ALL. Blood. 2013;122(8):1366–75. https://doi.org/10.1182/blood-2012-07-379016.CrossRefPubMed

• O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–101. https://doi.org/10.1002/cncr.23819. Showed worse outcomes for older patients treated with the intensive hyper-CVAD regimen, driven largely by myelosuppression-related deaths.CrossRefPubMedPubMedCentral

Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017;129(13):1878–81. https://doi.org/10.1182/blood-2016-11-749507.CrossRefPubMedPubMedCentral

10.

Li S, Molony JT, Chia V, Katz AJ. Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% medicare ALL data. Blood. 2016;128(22):3981.

11.

Saillard C, Etienne A, Charbonnier A, D'Incan E, Rey J, Arnoulet C, et al. Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. Leuk Lymphoma. 2014;55(9):2211–2. https://doi.org/10.3109/10428194.2013.876497.CrossRefPubMed

12.

Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12(13):1249–57. https://doi.org/10.1016/s1470-2045(11)70040-7.CrossRefPubMed

13.

Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, et al. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10):1184–90. https://doi.org/10.1016/j.leukres.2014.06.018.CrossRefPubMedPubMedCentral

14.

Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001;67(2):73–83. https://doi.org/10.1002/ajh.1083.CrossRefPubMed

15.

Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, et al. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2016;123(3):459–67. https://doi.org/10.1002/cncr.30376.CrossRefPubMedPubMedCentral

16.

Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206–14. https://doi.org/10.1182/blood-2009-07-232124.CrossRefPubMed

17.

Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189–97. https://doi.org/10.1182/blood-2006-10-051912.CrossRefPubMed

18.

Igwe IJ, Yang D, Merchant A, Merin N, Yaghmour G, Kelly K, et al. The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era—a surveillance, epidemiology, and end results database analysis. Br J Haematol. 2017;179(4):618–26. https://doi.org/10.1111/bjh.14953.CrossRefPubMed

19.

Byun JM, Koh Y, Shin DY, Kim I, Yoon SS, Lee JO, et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. Haematologica. 2017;102(5):e187–e90. https://doi.org/10.3324/haematol.2016.159988. CrossRefPubMedPubMedCentral

20.

Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, et al. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017;123(19):3717–24. https://doi.org/10.1002/cncr.30810.CrossRefPubMed

21.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31(3):705–11. https://doi.org/10.1038/leu.2016.263. PubMed

22.

Ribera J, Morgades M, Zamora L, Montesinos P, Gomez-Segui I, Pratcorona M, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;121(21):3809–17. https://doi.org/10.1002/cncr.29579.CrossRefPubMed

23.

Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739–49. https://doi.org/10.1182/blood-2014-01-547695.CrossRefPubMed

24.

Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202–7. https://doi.org/10.1200/jco.2008.21.6408. CrossRefPubMed

25.

DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016;57(10):2298–306. https://doi.org/10.3109/10428194.2016.1144881.CrossRefPubMedPubMedCentral

26.

Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007;78(2):102–10. https://doi.org/10.1111/j.1600-0609.2006.00778.x. PubMed

27.

Goekbuget N, Leguay T, Hunault M, Al-Nawakil C, Chevallier P, Dombret H, et al. First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation. Blood. 2008;112(11):304.

28.

Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011;96(2):245–52. https://doi.org/10.3324/haematol.2010.027862.CrossRefPubMed

29.

•• Goekbuget N, Beck J, Brueggemann M, Burmeister T, Buss EC, Frickhofen N, et al. Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German multicenter study Group for Adult ALL (GMALL). Blood. 2012;120(21):1493. Largest prospective study of older patients with Ph-negative ALL.

30.

Ribera JM, Garcia O, Oriol A, Gil C, Montesinos P, Bernal T, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016;41:12–20. https://doi.org/10.1016/j.leukres.2015.11.012.CrossRefPubMed

31.

•• Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a single-arm, phase II study. Lancet Oncol. 2018 Jan 15. pii: S1470-2045(18)30011-1. doi: https://doi.org/10.1016/S1470-2045(18)30011-1. [Epub ahead of print] Showed high efficacy and promising long-term survival using novel agent (i.e. inotuzumab ozagamicin) in combination with low-intensity chemotherapy for elderly ALL.

32.

Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330–7. https://doi.org/10.1182/blood-2008-04-151860.CrossRefPubMedPubMedCentral

33.

Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044–53. https://doi.org/10.1056/NEJMoa1605085. CrossRefPubMed

34.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53. https://doi.org/10.1056/NEJMoa1509277. CrossRefPubMedPubMedCentral

35.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, et al. Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial. J Clin Oncol. 2016;34(15_suppl):7029. https://doi.org/10.1200/JCO.2016.34.15_suppl.7029.

36.

Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017;30(3):193–200. https://doi.org/10.1016/j.beha.2017.05.001.CrossRefPubMed

37.

Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489–96. https://doi.org/10.1182/blood-2009-01-199380.CrossRefPubMedPubMedCentral

38.

Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653–61. https://doi.org/10.3324/haematol.2014.118588.CrossRefPubMedPubMedCentral

39.

Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–9. https://doi.org/10.1182/blood-2015-02-627935.CrossRefPubMed

40.

Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–64. https://doi.org/10.1002/cncr.29646.CrossRefPubMedPubMedCentral

41.

Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–56. https://doi.org/10.1182/blood-2015-03-636548.CrossRefPubMed

42.

Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547–55. https://doi.org/10.1016/s1470-2045(15)00207-7.CrossRefPubMedPubMedCentral

43.

Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–21. https://doi.org/10.1182/blood-2012-11-466482.CrossRefPubMedPubMedCentral

44.

Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–7. https://doi.org/10.1182/blood-2016-03-707562.CrossRefPubMedPubMedCentral

45.

Short NJ, Kantarjian HM, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, et al. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. J Clin Oncol. 2017;35(15_suppl):7013. https://doi.org/10.1200/JCO.2017.35.15_suppl.7013.

46.

Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650–6. https://doi.org/10.1002/cncr.30231.CrossRefPubMedPubMedCentral

47.

Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91. https://doi.org/10.1016/j.leukres.2016.07.007.CrossRefPubMed

48.

Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676–8. https://doi.org/10.1182/blood-2006-10-052746.CrossRefPubMed

49.

Ottmann OG, Pfeifer H, Cayuela J-M, Spiekermann K, Beck J, Jung WE, et al. Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with <em>De Novo</em> Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02). Blood. 2014;124(21):798.

50.

•• Rousselot P, Coude MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774–82. https://doi.org/10.1182/blood-2016-02-700153. Showed feasability of TKI with low-intensity chemotherapy in older Ph-positive ALL. Also notable for high rate of T315I mutations at relapse.CrossRefPubMedPubMedCentral

51.

Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–8. https://doi.org/10.1182/blood-2011-05-351403.CrossRefPubMed

52.

Martinelli G, Piciocchi A, Papayannidis C, Paolini S, V R, Soverini S et al. First report of the Gimema LAL1811 Phase II Prospective Study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017.

53.

Speziali C, Paulson K, Seftel M. Hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep. 2016;11(3):175–84. https://doi.org/10.1007/s11899-016-0317-2.CrossRefPubMed

54.

Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(10):1283–300. https://doi.org/10.1038/bmt.2016.141.CrossRefPubMed

55.

Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9. https://doi.org/10.3324/haematol.2014.103655.CrossRefPubMedPubMedCentral

56.

• Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439–43. https://doi.org/10.1182/blood-2010-02-266551. Large study of older adults who underwent allogeneic stem cell transplantation for ALL.CrossRefPubMed

57.

Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017;92(1):42–9. https://doi.org/10.1002/ajh.24575.CrossRefPubMed

58.

Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. https://doi.org/10.1056/NEJMoa1609783. CrossRefPubMedPubMedCentral

59.

Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer. 2016;122(14):2178–85. https://doi.org/10.1002/cncr.30031.CrossRefPubMed

60.

Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897–901. https://doi.org/10.1016/j.clml.2017.08.101.CrossRefPubMed

61.

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22. https://doi.org/10.1056/NEJMoa1513257. CrossRefPubMed

62.

Wei A, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL, et al. Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged ≥65 years with acute myeloid leukemia. Blood. 2016;128(22):102.

63.

Pollyea DA, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA, et al. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy. J Clin Oncol. 2016;34(15_suppl):7009. https://doi.org/10.1200/JCO.2016.34.15_suppl.7009.

64.

Scherr M, Elder A, Battmer K, Barzan D, Bomken S. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia. 2014;28(3):554–65. https://doi.org/10.1038/leu.2013.361. CrossRefPubMed

65.

Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75(7):1366–75. https://doi.org/10.1158/0008-5472.can-14-1849.CrossRefPubMedPubMedCentral

66.

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8(354):354ra114. https://doi.org/10.1126/scitranslmed.aaf5309.CrossRefPubMed

67.

Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O’Brien S, Kantarjian H. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol 2017. https://doi.org/10.1001/jamaoncol.2017.2380.

Title: Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia
Authors: Nicholas J. Short
Hagop Kantarjian
Elias Jabbour
Farhad Ravandi
Publication date: 01-04-2018
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 2/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0440-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies

Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia

Update on the Treatment of Anaplastic Large Cell Lymphoma

Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient: a Focus on Delirium

Frontline Therapy of CLL: Evolving Treatment Paradigm

Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage